More Than a Medical Rebrand: Understanding the Move from PCOS to PMOS
What if one medical term has been shaping the way millions of people misunderstand their own health? Sometimes, changing a name is not about branding. It is about correcting decades of confusion. The proposed transition from Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) has sparked global conversations, raising an important question. Can a new name improve diagnosis, treatment, and awareness?
After an international consultation involving clinicians, researchers, and people living with the condition, experts recommended replacing the name PCOS with PMOS. The proposal reflects growing scientific understanding that the condition is not defined by ovarian cysts alone, but by a complex interaction of hormonal, metabolic, and reproductive factors.
For decades, the term “polycystic ovary” has unintentionally created misconceptions. Many women assumed that the absence of ovarian cysts meant they could not have the condition. However, international diagnostic guidelines confirm that ovarian cysts are only one of several possible features, and many patients are diagnosed without them.
According to the 2023 International Evidence-based Guideline for PCOS, jointly developed by organisations including Monash University, the American Society for Reproductive Medicine (ASRM), and the European Society of Human Reproduction and Embryology (ESHRE), PCOS affects an estimated 8 to 13 percent of women of reproductive age worldwide. Yet up to 70 percent remain undiagnosed, often because symptoms are misunderstood or dismissed.
The proposed name PMOS highlights what researchers increasingly recognise. Insulin resistance, chronic inflammation, hormone imbalance, and increased risks of type 2 diabetes and cardiovascular disease are often central to the condition. Symptoms such as irregular menstruation, acne, excessive hair growth, weight changes, infertility, anxiety, and depression are frequently interconnected rather than isolated reproductive problems.
As one expert message behind the proposal suggests, “The condition is much more than cysts.” That shift in language may encourage both healthcare providers and patients to adopt a more holistic understanding of women’s health.
Still, experts caution that changing a name alone will not solve delayed diagnosis or unequal access to healthcare. Public awareness, updated clinical training, affordable screening, and evidence-based treatment remain equally important.
For countries like Bangladesh, where discussions on menstrual and reproductive health are still surrounded by stigma, clearer language could play an important role in encouraging earlier care-seeking and improving Sexual and Reproductive Health and Rights (SRHR). If the conversation moves beyond fertility and focuses on lifelong metabolic health, the change could benefit millions of women who have long felt unseen.
Sometimes, the biggest medical breakthrough is not a new medicine. It is helping people understand the condition they have been living with all along.
Source: The Daily Star
